Stay updated on Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.

Latest updates to the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page
- Check7 days agoChange DetectedThe page's revision tag was updated from v3.5.3 to v3.5.4, indicating a new release/patch was applied. This update relates to site metadata rather than changes to study data or visible content.SummaryDifference0.0%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedThe page now displays an updated “Revision” version number for the ClinicalTrials.gov interface (from v3.5.2 to v3.5.3). This represents a platform/version update rather than a modification to the trial record itself.SummaryDifference0.0%

- Check36 days agoChange DetectedAdded Revision: v3.5.2 and removed Revision: v3.5.0 in the history log.SummaryDifference0.0%

- Check65 days agoChange DetectedAdded Revision: v3.5.0 and removed Revision: v3.4.3 from the page history.SummaryDifference0.0%

- Check79 days agoChange DetectedA new revision entry, Revision: v3.4.3, was added and the previous Revision: v3.4.2 entry was removed.SummaryDifference0.0%

- Check101 days agoChange DetectedThe page now displays Revision: v3.4.2, replacing the previous Revision: v3.4.1.SummaryDifference0.0%

Stay in the know with updates to Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab/Lenvatinib vs Docetaxel in NSCLC Clinical Trial page.